topics

Sep,21 2018
Astellas Announces Approval in Japan for XOSPATA® 40mg Tablets for the Treatment of FLT3mut+ Relapsed or Refractory AML
Aug,17 2018
Receive marketing approval in Japan.
RAMATROBAN TAB. 50mg「KO」
RAMATROBAN TAB. 75mg「KO」
LORNOXICAM TAB. 2mg「KO」
LORNOXICAM TAB. 4mg「KO」
Jun,15 2018
Newly-marketed drug
FLECAINIDE ACETATE TAB. 50mg「KO」
FLECAINIDE ACETATE TAB. 100mg「KO」
May,29 2018
U.S. FDA Grants Priority Review to New Drug Application for Gilteritinib for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
May,22 2018
SUJANU® Combination Tablets released -Drug combining selective DPP-4 inhibitor and selective SGLT2 inhibitor-
Apr,24 2018
New Drug Applications for Approval of Gilteritinib for the Treatment of FLT3mut+ Relapsed or Refractory Acute Myeloid Leukemia ware submitted in Japan.
Mar,23 2018
SUJANU® Combination Tablets combining type-2 diabetes drugs receive marketing approval in Japan.
Mar,22 2018
The Japanese MHLW Grants Orphan-Drug Designation for Development of FLT3 Inhibitor Gilteritinib in Acute Myeloid Leukemia.
Feb,15 2018
Receive marketing approval in Japan.
FLECAINIDE ACETATE TAB. 50mg「KO」
FLECAINIDE ACETATE TAB. 100mg「KO」
Feb,11 2018
MARZULENE-S (China name: 麦滋林TM) for the treatment of gastritis and ulcer exported to China has been certified as an international reference product and original imported product from China National Food and Drug Administration Supervision and Administration Administration (CFDA).
Jan,23 2018
European Commission Grants Orphan-Drug Designation for Development of FLT3 Inhibitor Gilteritinib in Acute Myeloid Leukemia.
Dec,8 2017
Newly-marketed drug
TORASEMIDE TAB. 4mg「K0」
TORASEMIDE TAB. 8mg「K0」
Oct,11 2017
U.S. FDA Grants Fast Track Designation to Astellas for Development of Gilteritinib in Relapsed or Refractory Acute Myeloid Leukemia.
Jul,21 2017
U.S. FDA Grants Orphan-Drug Designation for Development of FLT3 Inhibitor Gilteritinib in Acute Myeloid Leukemia.
May,22 2017
Submits application for approval of type-2 diabetes drug combining selective SGLT2 inhibitor “Suglat® Tablets” and selective DPP-4 inhibitor “JANUVIA® Tablets” .(Joint development with Astellas Pharma Inc. and MSD )
Dec,09 2016
Newly-marketed drug
MONTELUKAST TAB. 5mg「KO」
MONTELUKAST TAB. 10mg「KO」
Jun,17 2016
Newly-marketed drug
LOSARHYD COMBINATION TAB. HD「KO」
Jun,19 2015
Newly-marketed drug
CLOPIDOGREL TAB. 25mg「KO」
CLOPIDOGREL TAB. 75mg「KO」
Dec,12 2014
Newly-marketed drug
CANDESARTAN TAB. 2mg「KO」
CANDESARTAN TAB. 4mg「KO」
CANDESARTAN TAB. 8mg「KO」
CANDESARTAN TAB. 12mg「KO」
Jun,20 2014
Newly-marketed drug
CILOSTAZOL OD TAB. 50mg「KO」
CILOSTAZOL OD TAB. 100mg「KO」
PITAVASTATIN CALCIUM TAB. 4mg「KO」
LOSARHYD COMBINATION TAB. LD「KO」
Apr,17 2014
Newly-marketed drug
Suglat Tablets 25mg
Suglat Tablets 50mg
Dec,13 2013
Newly-marketed drug
DONEPEZIL HYDROCHLORIDE OD TAB. 10mg「KO」
PITAVASTATIN CALCIUM TAB. 1mg「KO」
PITAVASTATIN CALCIUM TAB. 2mg「KO」
Nov,18 2013
Anticancer drug (ASP2215) (Phase1, development by Astellas Pharma Inc.)
Anticancer drug (ASP5878) (Phase1, development by Astellas Pharma Inc.)
Jun,21 2013
Newly-marketed drug
PAROXETINE TAB. 5mg「KO」
PRAMIPEXOLE HYDROCHLORIDE TAB. 0.125mg「K0」
PRAMIPEXOLE HYDROCHLORIDE TAB. 0.5mg「K0」
Mar,13 2013
Submits Application for Marketing Approval of Ipragliflozin (ASP1941)/SGLT2 Inhibitor for Treatment of Type 2 Diabetes(Joint development with Astellas Pharma Inc.), in Japan.
Dec,14 2012
Newly-marketed drug
OLOPATADINE HYDROCHLORIDE TAB. 2.5mg「KO」
OLOPATADINE HYDROCHLORIDE TAB. 5mg「KO」
MOSAPRIDE CITRATE TAB. 2.5mg「KO」
MOSAPRIDE CITRATE TAB. 5mg「KO」
Oct,30 2012
We changed development number of cholesterol absorption inhibitor KT6-971 to S-556971.
Jun,22 2012
Newly-marketed drug
PAROXETINE TAB. 10mg「KO」
PAROXETINE TAB. 20mg「KO」
PIOGLITAZONE TAB. 15mg「KO」
PIOGLITAZONE TAB. 30mg「KO」
Nov,28 2011
Newly-marketed drug
Donepezil Hydrochloride OD Tablets 3mg「KO」
Donepezil Hydrochloride OD Tablets 5mg 「KO」
Jul,20 2011
Newly-marketed drug
AZULOXA TAB. 15mg
KIRIGAMIL Nasal Solution 50μg 56 mists
Jun,24 2011
AZULOXA TAB. 15mg and KIRIGAMIL Nasal Solution 50μg 56 mists.It was listed in the drug price list in Japan.
Nov,19 2010
Newly-marketed drug
FENOFIBRATE CAP. 67mg「KTB」
FENOFIBRATE CAP. 100mg「KTB」
GLIMEPIRIDE TAB. 1mg「KO」
GLIMEPIRIDE TAB. 3mg「KO」
PORATILE 1mg TAB.
Jun,28 2010
That the efficacy and safety of ASP-1941 were validated by the Japanese phase Ⅱb and American Phase IIa was presented at American Diabetes Association.
May,28 2010
Newly-marketed drug
SARPOGRELATE HYDROCHLORIDE TAB. 50mg「KTB」
SARPOGRELATE HYDROCHLORIDE TAB. 100mg「KTB」
Mar,22 2010
A lecture was given on KT6-971, a next generation cholesterol absorption inhibitor, at American Chemical Society, which was also featured by New Current 21.
Nov,13 2009
Newly-marketed drug
MARZULENE CONBINATION TABLETS 0.375 ES
Aug,06 2009
American Chemical Society requested us to give a lecture as a guest speaker on KT6-971, a newly developed item, at a session of next generation cholesterol absorption inhibitors.
Apr,06 2009
AZULOXA granules 2.5%, developed by our company,were launched onto the market together with Ajinomoto Co., Inc.